AGEN Reports $4.2M Early Access Revenue, $21M Median OS in MSS mCRC, Phase 3 BOT+BAL Trial Launched, France Expands Reimbursement
Agenus Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.48
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS